Follow
Helmut Butzkueven
Helmut Butzkueven
MSNI Research Group, Dept of Neuroscience, Central Clinical School, Monash University
Verified email at monash.edu
Title
Cited by
Cited by
Year
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Nature 476 (7359), 214-219, 2011
26252011
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ...
Nature genetics 45 (11), 1353-1360, 2013
11222013
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ...
Neurology 64 (7), 1144-1151, 2005
9362005
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, R Simmons, ...
Bmj 327 (7410), 316, 2003
6902003
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
6022018
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
CL Martin, BA Phillips, TJ Kilpatrick, H Butzkueven, N Tubridy, ...
Multiple Sclerosis Journal 12 (5), 620-628, 2006
5952006
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20
Data analysis: Bahlo Melanie 2 Brown Matthew A 6 7 Browning Brian L 20 ...
Nature genetics 41 (7), 824-828, 2009
5052009
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, BV Taylor, T Kilpatrick, ...
Journal of neurology 254 (5), 581-590, 2007
3982007
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci
NA Patsopoulos, ...
Annals of neurology 70 (6), 897-912, 2011
3272011
Brain health: time matters in multiple sclerosis
G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ...
Multiple sclerosis and related disorders 9, S5-S48, 2016
3132016
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival
H Butzkueven, JG Zhang, M Soilu-Hanninen, H Hochrein, F Chionh, ...
Nature medicine 8 (6), 613-619, 2002
3052002
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
2672019
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
2412016
Onset seizures independently predict poor outcome after subarachnoid hemorrhage
H Butzkueven, AH Evans, A Pitman, C Leopold, DJ Jolley, AH Kaye, ...
Neurology 55 (9), 1315-1320, 2000
2352000
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PLOS one 7 (10), e48078, 2012
2222012
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
MS Stein, Y Liu, OM Gray, JE Baker, SC Kolbe, MR Ditchfield, GF Egan, ...
Neurology 77 (17), 1611-1618, 2011
2112011
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ...
The Lancet Neurology 16 (3), 189-199, 2017
2032017
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
H Butzkueven, J Chapman, E Cristiano, F Grand’Maison, M Hoffmann, ...
Multiple Sclerosis Journal 12 (6), 769-774, 2006
1722006
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
H Butzkueven, L Kappos, F Pellegrini, M Trojano, H Wiendl, RN Patel, ...
Journal of Neurology, Neurosurgery & Psychiatry 85 (11), 1190-1197, 2014
1682014
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of Neurology 77 (3), 425-435, 2015
1592015
The system can't perform the operation now. Try again later.
Articles 1–20